AbstractBySubCategory

Non-Hodgkin Lymphoma

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2016 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial. Lorenz H. Trumper

7500

A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL). Adrienne Alise Phillips

7501

Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. James L. Rubenstein

7502

Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). Mathias J. Rummel

7503

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. Pieternella J. Lugtenburg

7504

PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). Thomas E. Witzig

7506

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). Andrew M. Evens

7507

Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. David W. Scott

7510

Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. David Matthew Kurtz

7511

Long-term follow-up of the PI3Kδ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. Howard A. Burris

7512

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. Michael Crump

7516

Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study. Nicolas Mounier

7518

Participation in clinical trials to improve outcomes of patients with relapsed lymphoma. Grzegorz S. Nowakowski

7523

Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST). Grzegorz S. Nowakowski

7538

Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL. Florian Zettl

7539

Effect of antiviral therapy on overall survival in hepatitis c virus-infected patients with diffuse large b-cell lymphoma. Jeff Hosry

7540

Outcomes and prognostic factors of radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) for newly diagnosed, localized extranodal NK/T-cell lymphoma, nasal type (ENKL): a cooperative study in Japan. Motoko Yamaguchi

7541

Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL). Kunihiro Tsukasaki

7542

Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. Theresa H.M. Keegan

7543

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL). Narendranath Epperla

7544

Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin’s lymphoma (R-R NHL). Wojciech Jurczak

7545

Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma. Gita Thanarajasingam

7546

Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system. Karen Leroy

7547

The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. Constantine Si Lun Tam

7548

A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. Ahmed Sawas

7549

Lymphoma-associated mortality in the German HIV-lymphoma cohort study. Marcus Hentrich

7550

Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). Issa F. Khouri

7551

Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM). Jonas Paludo

7552

A phase II prospective clinical study of the “sandwich” protocol, VDLP combined with concurrent radiation and cisplatin in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Li Zhang

7553

Noninvasive molecular subtyping and risk stratification of DLBCL. Florian Scherer

7554

Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. Robert W. Chen

7555

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110. Jean-Marie Michot

7556

Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies—Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing. Paul A. Hamlin

7557

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. Francine M. Foss

7558

Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). Sattva Swarup Neelapu

7559

Application of multi-agent CT among patients with leg-type primary cutaneous B-cell lymphoma. Sarah Swati Pai

7560

Sandwich-like gemcitabine, dexamethasone, and cisplatin(GDP) chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, upper aerodigestive tract natural killer/T-cell lymphoma. Shu Tian

7561

A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results. Madeleine Duvic

7562

Outcomes of diffuse large b-cell lymphoma with MYC and/or BCL2 protein expression treated with intensive chemotherapy. Amir Issa

7563

Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). Stephen J. Schuster

7564

Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma. I Brian Greenwell

7565

Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma. Andrew David Zelenetz

7566

Deferred treatment as a viable option for selected patients with mantle cell lymphoma. Oscar Calzada

7567

Outcomes of patients with diffuse large B-cell lymphoma treated with immunochemotherapy based on cell of origin. Avyakta Kallam

7568

EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC). Line Srour

7569

Clinicopathologic features and survival outcomes of secondary diffuse large b-cell lymphoma after a primary solid malignancy: SEER propensity-matched analysis. Muhammad Saad Hamid

e19022

Efficacy and safety of examethasone, high dose cytarabine, and carboplatin (DHAC) with and without rituximab (R) as a salvage regimen for relapsed/refractory (R/R) lymphoma. Jeffrey Baron

e19023

Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma. Sung Hsin Kuo

e19024

Integrated infectious toxicity analysis of the BTK inhibitor ibrutinib. James Michael Pauff

e19025

The incidence, prognosis and survival of primary breast lymphoma: A SEER experience. Vivek Kumar

e19026

Incidence and risk factors for ibrutinib associated atrial fibrillation. Josephine Ngozi Emole

e19028

Pre-cancer cardiovascular risk factors and anthracycline-related cardiotoxicity among non-Hodgkin lymphoma survivors. Talya Salz

e19031

Prognostic impact of CD3 infiltrating t-cells in the tumor microenvironment with clinical factors for solid organ transplant (SOT) recipients with post-transplant lymphoproliferative disorders (PTLD). Ryan Stubbins

e19033

Localized orbital adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation and rituximab: a single institute experience. Maria Chaudhry

e19034

Single center experience of 90Y-Ibritumomab tiuxetan in the older population with non-hodgkin lymphoma. Vaibhav Agrawal

e19035

NK/T cell lymphoma in the U.S: A population-based study using the National Cancer Database from 1998-2012. Amritha C. Karkera

e19038

Rituximab-induced hepatitis C virus reactivation in HCV-positive patients with diffuse large B-cell lymphoma. Rasha Mohamed Haggag

e19039

Flt3L-based in situ vaccination for the treatment of lymphoma. Linda Hammerich

e19040

A new prognostic model for nasal-type, extranodal natural killer/T cell lymphoma. Na Li

e19042

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated with R-ICE based on dual expression of MYC and BCL2. Joshua M. Allen

e19043

The prognostic impact of serum albumin in double hit/double expressing aggressive B cell lymphomas: A pilot study evaluating SAAB scoring system. Chetasi Talati

e19044

Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: A Peruvian experience. Luis Ernesto Cuellar Ponce de León

e19045

Phase I/II study of an anti-CD20-interleukin-2 immunocytokine DI-Leu16-IL2 in patients with relapsed b-cell lymphoma (NHL). Frederick Lansigan

e19046

Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan. Kenichi Ishizawa

e19050

Patterns of recurrence in primary central nervous system lymphoma: Mechanistic inferences. Prakash Ambady

e19051

Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma. Carla Casulo

e19052

Successful treatment in primary central nervous system lymphoma. Erden Atilla

e19053

Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga). Adrienne Alise Phillips

e19056

Role of FDG-PET/CT and gastrointestinal endoscopy in the staging of diffuse large B-cell lymphoma (DLBCL): Expanded data. Tadahiro Honda

e19057

Differential response to radiation treatment in molecular subtypes of diffuse large B-Cell lymphoma (DLBCL). Elaine Patricia Lunsford

e19058

Development of non-Hodgkin lymphoma as a second primary cancer in patients with chronic hepatitis C virus infection. Minas P. Economides

e19059

Clinical significance of gastrointestinal involvement in human immunodeficiency virus (HIV) patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Abdul Rafeh Naqash

e19060

Association of activated BCR and PI3K pathways with responses and longer PFS to single-agent copanlisib in heavily pretreated patients with indolent and aggressive NHL. LI Liu

e19063

Phase I study of recombinant human interleukin-18 (IL-18) in combination with ofatumumab after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoma. Michael J. Robertson

e19066

Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma. Sean I. Tracy

e19067

The serum albumin and gender in patients with low risk NCCN-IPI diffuse large B-cell lymphoma. Branimir Spassov

e19068

Synergistic cytotoxic effects of selinexor and chloroquine phosphate in mantle cell lymphoma. Yongyi Zhang

e19069

A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study. Kiyohiko Hatake

e19070

A rare manifestation: Primary mediastinal large-b cell lymphoma. Erden Atilla

e19071

Association between cocaine use and hematological malignancies. Amandeep Singh Aujla

e19072

Bone marrow involvement in mantle cell lymphoma: An immunophenotyping analysis with clinicopathologic correlation from a tertiary care center in North India. CHANDAN KRUSHNA DAS

e19073

Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma. Jason R. Westin

TPS7575

A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs). Philippe Armand

TPS7576

A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study. Jason R. Westin

TPS7577

FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen. Nathan Hale Fowler

TPS7578

Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma. Daniel Jeffrey Landsburg

TPS7579

A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL). Ki Y. Chung

TPS7580

First-in-class small molecule ONC201 in b-cell malignancies. Hun Ju Lee

TPS7581

Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Franck Morschhauser

TPS7582

OAsIs: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma. Steven Le Gouill

TPS7583

A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT). Robert W. Chen

TPS7584